Monitor Nasdaq listing approval and the second closing of the Streeterville Capital facility, which would provide $5M in funding. The company's ability to continue as a going concern depends on that listing and funding. Watch for stockholder vote on the full $30M Streeterville commitment and potential dilution from the convertible preferred and warrant.
How similar events traded
Executive Summary
Med-X, Inc. filed Amendment No. 3 to its S-1 registration statement for a direct listing on Nasdaq. The company registers 16,248,842 post-split shares for resale by existing stockholders; the company will receive no proceeds. The filing updates the share count from 13,183,842 in the prior amendment and reflects the Streeterville Capital equity facility amendment. The company has a history of net losses, an accumulated deficit of $55.4M as of June 30, 2026, and its auditor included a going concern explanatory paragraph for FY2025.
Key Financial Metrics
Key Facts
- Amendment No. 3 to S-1 for direct listing on Nasdaq Global Market under symbol MXRX
- Registers 16,248,842 post-split shares for resale by existing stockholders; company receives no proceeds
- Share count increased from 13,183,842 in prior amendment (Oct 29) and 13,052,103 in original S-1 (Sep 28)
- Streeterville Capital equity facility amended Nov 2, 2026: $10,000 warrant purchase price paid, 25,000 commitment shares and warrant for 1,500,000 shares at $10.00 issued at first closing; $5,000,000 Series B Convertible Preferred Stock funding at second closing contingent on Nasdaq listing
- Net revenue $1.03M for H1 2026 (up 16.3% YoY from $0.89M), net loss $7.66M (up from $4.14M YoY, primarily non-cash stock-based compensation of $5.08M)
- Accumulated deficit $55.38M as of June 30, 2026; cash $1.50M; working capital $1.77M
- Auditor Cherry Bekaert LLP included going concern explanatory paragraph for FY2025 financial statements
- CEO Matthew Mills controls 51% voting power through Series A super voting preferred stock
- 1-for-2 reverse stock split to be effected prior to listing
Financial Impact
H1 2026 net revenue $1.03M, net loss $7.66M (incl. $5.08M non-cash stock-based comp); accumulated deficit $55.38M; cash $1.50M
Risk Factors
- Nasdaq listing approval not assured; if denied, the direct listing terminates and Streeterville funding does not occur
- Going concern risk: accumulated deficit $55.4M, operating losses continue, cash $1.5M may not sustain operations without Streeterville funding
- Potential substantial dilution from Streeterville Series B Convertible Preferred Stock and warrant (1.5M shares at $10.00)
- CEO controls 51% voting power via super voting preferred stock, limiting other stockholders' influence
- Customer concentration: 31% of FY2025 revenue from two customers; no written distribution agreements
- Supplier concentration: 80% of purchases from two vendors in FY2025
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001477932-26-006714 |
| Document: medx_ex1034.htm | 0001477932-26-006714 |
| Document: 0001477932-26-006714-index-headers.html | 0001477932-26-006714 |
| Document: 0001477932-26-006714-index.html | 0001477932-26-006714 |
| Document: 0001477932-26-006714.txt | 0001477932-26-006714 |
Track record
2 reports on MXRX
Filters
- Nov 17, 2026today S-1/A Neutral 5/10 Entry price pending
- Nov 5, 202612d ago S-1/A Neutral 5/10 Viewing No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers